AVROBIO, Inc. announced the appointment of Sean O'Bryan as chief regulatory officer. Previously, O'Bryan was senior vice president, head of Regulatory Affairs & Quality Assurance at Axovant (now Sio Gene Therapies), leading all regulatory and quality work for multiple vector-based gene therapy programs and serving as project lead for the lysosomal disease programs. He also advanced the regulatory process for multiple cell and gene therapy programs in his previous roles as vice president, head of Regulatory Affairs and Quality Assurance at Lysogene, senior director of Regulatory Affairs and head of Regulatory CMC at bluebird bio and director, Regulatory Affairs at Sanofi/Genzyme.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.47 USD | -0.12% | -3.17% | +0.92% |
06-20 | Avrobio Closes Merger With Tectonic Therapeutic | MT |
06-20 | Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.92% | 243M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- AVRO Stock
- News Tectonic Therapeutic, Inc.
- AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer